Table 4 Outcomes after salvage therapy for local recurrence
From: Reassessment of intensive surveillance practices adopted for endometrial cancer survivors
| Â | No recurrence | Die after recurrence | p-value |
|---|---|---|---|
Age | 58 [41–78] | 67 [51–79] | 0.086** |
Initail stage | Â | Â | 0.091* |
 1a | 4 | 0 |  |
 1b | 0 | 3 |  |
 2 | 0 | 1 |  |
 3a | 3 | 0 |  |
 3c | 4 | 1 |  |
 4b | 0 | 1 |  |
Histology | Â | Â | 0.655* |
 Endometrioid G1-2 | 8 | 5 |  |
 Endometrioid G3 | 2 | 1 |  |
 Carcinosarcoma | 1 | 0 |  |
Time to recurrence (day) | 1,099 [27–2,118] | 226 [167–1,000] | 0.021** |
 Shcedulled visit at recurrence |  |  | 0.091* |
  No | 4 | 0 |  |
  Yes | 7 | 6 |  |
Symptom at recurrence | Â | Â | 0.064* |
 No | 4 | 5 |  |
 Yes | 7 | 1 |  |
Treatment after recurrence | Â | Â | 0.434* |
 Supprotive care | 0 | 1 |  |
 Radiation | 10 | 4 |  |
 Chemotherapy | 1 | 1 |  |